BAFNAPH

BAFNA PHARMACEUTICALS

Small Cap BSE: 532989 NSE: BAFNAPH
₹102.9
3.8 (3.83%)
As on 30 September, 2022 | 03:35

Bafna Pharmaceuticals Share Price

Bafna Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in BAFNA PHARMACEUTICALS

Start SIP

Bafna Pharmaceuticals Share Returns

  • Over 1 Month -13.83%
  • Over 3 Month -15.02%
  • Over 6 Month -22.1%
  • Over 1 Year -23.04%

Bafna Pharmaceuticals Key Statistics

P/E Ratio 55
PEG Ratio -2
Market Cap Cr 243
Price to Book Ratio 3.9
EPS 3.1
Dividend 0
Relative Strength Index 21.61
Money Flow Index 4.98
MACD Signal -2.79
Average True Range 5.54

Bafna Pharmaceuticals Investment Rating

  • Master Rating:
  • Bafna Pharmaceuticals has an operating revenue of Rs. 80.81 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 6% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 13 which is a POOR score indicating inconsistency in earnings, a RS Rating of 9 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has some strength but we want to see some buyer interest and further fundamental performance to qualify as a growth stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 171520282122
Operating Expenses Qtr Cr 151618231818
Operating Profit Qtr Cr 2-13634
Depreciation Qtr Cr 111111
Interest Qtr Cr 000000
Tax Qtr Cr 000000
Net Profit Qtr Cr 1-12223

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
99.05
-0.05 (-0.05%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 105.05
  • 50 Day
  • 109.56
  • 100 Day
  • 114.92
  • 200 Day
  • 125.52
  • 20 Day
  • 106.26
  • 50 Day
  • 109.87
  • 100 Day
  • 114.79
  • 200 Day
  • 125.55

Bafna Pharmaceuticals Resistance and Support

PIVOT
₹100.34
Resistance
First Resistance 102.67
Second Resistance 106.24
Third Resistance 108.57
RSI 21.61
MFI 4.99
MACD Single Line -2.79
MACD -3.55
Support
First Resistance 96.77
Second Resistance 94.44
Third Resistance 90.87

Bafna Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 3,178 317,800 100
Week 1,822 182,240 100
1 Month 4,012 401,238 100
6 Month 3,598 327,868 91.12

Bafna Pharmaceuticals Result Highlights

Bafna Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Bafna Pharmaceutical belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 71.22 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2021. Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698.
Market Cap 234
Sales 81
Shares in Float 0.24
No of funds
Yield
Book Value 3.73
U/D Vol ratio 0.9
LTDebt / Equity 13
Alpha -0.06
Beta 0.89

Bafna Pharmaceuticals

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 90.12%90.42%90.42%
Individual Investors 5.5%5.24%6.09%
Others 4.38%4.34%3.49%

Bafna Pharmaceuticals Management

Name Designation
Mrs. S Hemalatha Chairperson & Executive Director
Mr. Atul Sachdeva Non Exe.Non Ind.Director
Mrs. Akila C Raju Non Exe.Non Ind.Director
Ms. R Chitra Ind. Non-Executive Director
Mr. B Kamlesh Kumar Ind. Non-Executive Director
Mr. P K Sundaresan Ind. Non-Executive Director

Bafna Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Bafna Pharmaceuticals Corporate Action

Date Purpose Remarks
2022-08-11 Quarterly Results
2022-05-26 Audited Results
2022-02-10 Quarterly Results
2021-11-12 Quarterly Results & Rights issue Inter alia, To consider and approve the proposal for various avenues for raising funds, including and in particular Rights Issue to meet capital requirements of the Company.
2021-09-16 Others Inter alia, to consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair.

Bafna Pharmaceuticals FAQs

What is Share Price of Bafna Pharmaceuticals ?

Bafna Pharmaceuticals share price is ₹102 As on 30 September, 2022 | 03:21

What is the Market Cap of Bafna Pharmaceuticals ?

The Market Cap of Bafna Pharmaceuticals is ₹243.4 Cr As on 30 September, 2022 | 03:21

What is the P/E ratio of Bafna Pharmaceuticals ?

The P/E ratio of Bafna Pharmaceuticals is 55 As on 30 September, 2022 | 03:21

What is the PB ratio of Bafna Pharmaceuticals ?

The PB ratio of Bafna Pharmaceuticals is 3.9 As on 30 September, 2022 | 03:21

Q1FY23